李健,刘芳欣,戚建国,许廷兰,任永凤,王洲,陈飞,李姿灼.卵巢-附件报告和数据系统超声2022版(O-RADS US v2022)及其联合恶性风险指数4鉴别附件良、恶性肿瘤[J].中国医学影像技术,2024,40(6):893~897
卵巢-附件报告和数据系统超声2022版(O-RADS US v2022)及其联合恶性风险指数4鉴别附件良、恶性肿瘤
Ovarian-adnexal reporting and data system ultrasound 2022 version (O-RADS US v2022) and it combined with risk of malignancy index 4 for differential diagnosis of benign and malignant adnexal tumors
投稿时间:2023-12-27  修订日期:2024-02-26
DOI:10.13929/j.issn.1003-3289.2024.06.020
中文关键词:  卵巢肿瘤  病理学,临床  诊断,鉴别  卵巢-附件报告和数据系统  恶性风险指数4
英文关键词:ovarian neoplasms  pathology, clinical  diagnosis, differential  ovarian-adnexal reporting and data system  risk of malignancy index 4
基金项目:
作者单位E-mail
李健 亳州市人民医院超声医学科, 安徽 亳州 236800  
刘芳欣 亳州市人民医院超声医学科, 安徽 亳州 236800 240104266@qq.com 
戚建国 亳州市人民医院超声医学科, 安徽 亳州 236800  
许廷兰 亳州市人民医院超声医学科, 安徽 亳州 236800  
任永凤 亳州市人民医院超声医学科, 安徽 亳州 236800  
王洲 亳州市人民医院超声医学科, 安徽 亳州 236800  
陈飞 亳州市人民医院超声医学科, 安徽 亳州 236800  
李姿灼 皖南医学院医学影像学院医学影像学系, 安徽 芜湖 241002  
摘要点击次数: 102
全文下载次数: 116
中文摘要:
      目的 观察卵巢-附件报告和数据系统超声2022版(O-RADS US v2022)及其联合恶性风险指数4(RMI4)鉴别附件良、恶性肿瘤的价值。方法 回顾性分析126例手术病理诊断为附件肿瘤患者,根据O-RADS US v2022将1~3类归为良性病变、4~5类归为恶性病变,以450为RMI4分类的临界值,基于二者进行联合分类。以病理结果为金标准,绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),评估单一O-RADS US v2022、RMI4及其联合鉴别附件良、恶性肿瘤的效能。结果 126例附件肿瘤中,良性94例、恶性32例。O-RADS US v2022鉴别附件良、恶性肿瘤的敏感度、特异度、准确率及AUC分别为78.13%、80.85%和80.16%、0.795,RMI4分别为71.88%、84.04%和80.95%、0.780;二者联合的特异度及准确率(93.62%、92.06%)均高于单一O-RADS US v2022(χ2=7.322、5.967,P=0.007、0.015)或RMI4(χ2=4.625、5.331,P=0.032、0.021),而敏感度及AUC(87.50%、0.906)差异均无统计学意义(P均>0.05)。结论 O-RADS US v2022能有效鉴别附件良、恶性肿瘤,联合RMI4可提高鉴别特异度及准确率。
英文摘要:
      Objective To observe the value of ovarian-adnexal reporting and data system ultrasound 2022 version (O-RADS US v2022) and it combined with risk of malignancy index 4 (RMI4) for differential diagnosis of benign and malignant adnexal tumors. Methods Data of 126 patients with adnexal tumors confirmed by surgical pathology were retrospectively analyzed. O-RADS US v2022 was used to classify: 1—3 as benign lesion and 4—5 as malignant lesion. RMI4 classification took 450 as the critical value. And classification was performed based on the two combination. Taking pathological results as gold standard, receiver operating characteristic (ROC) curve was drawn to evaluate the efficacy of O-RADS US v2022 and RMI4 alone or combination for the differential diagnosis of benign and malignant adnexal tumors. Results Among 126 cases, 94 were benign and 32 were malignant tumors. The sensitivity, specificity, accuracy and area under the curve (AUC) of O-RADS US v2022 were 78.13%, 80.85%, 80.16% and 0.795, respectively. The diagnostic results of RMI4 were 71.88%, 84.04%, 80.95% and 0.780, respectively. The specificity and accuracy of the combination of the two (93.62%, 92.06%) were higher than those of O-RADS US v2022 (χ2=7.322, 5.967, P=0.007, 0.015) or RMI4 (χ2=4.625, 5.331, P=0.032, 0.021), while no significant difference in sensitivity and AUC (87.50%, 0.906) was found with O-RADS US v2022 or RMI4 (all P>0.05). Conclusion O-RADS US v2022 could effectively differentiate benign and malignant adnexal tumors, and combined with RMI4 could improve the diagnostic specificity and accuracy.
查看全文  查看/发表评论  下载PDF阅读器